VACCINES

 

Vaccines are one of the greatest public health success stories of the 20th century, and MSD has played its part in that story.

Our contributions include the prevention of now rare diseases, like measles and mumps, to diseases never thought preventable, like shingles and cervical cancer.

MSD vaccines are now (as of 3 January 2017) supplied through our designated wholesaler, AAH Pharmaceuticals Ltd. If you do not currently have an account, you will need to set one up. For more information or to set up an account, please contact AAH Customer Care on 0344 561 8899 or visit the website at www.aah.co.uk

Please click here for the latest vaccines stock status.

HBVAXPRO™ supply statement

A combination of growing global demand for hepatitis B vaccines, and supply capacity constraints due to growing global demand of our other vaccines have led to interruptions in the supply of the MSD hepatitis B vaccine HBVAXPRO™ 10mcg in the UK.

On 26th February 2018, Public Health England (PHE) published a ‘Plan for phased re-introduction of hepatitis B vaccine for lower priority groups in 2018’ (Gateway reference 2017806), which outlines advice to support providers, including GPs and occupational health services, to plan vaccination for new and existing patients and staff in priority group 4* for whom vaccination may have been deferred. This advice is available from https://www.gov.uk/government/publications/hepatitis-b-vaccine-recommendations-during-supply-constraints and should be read in conjunction with the PHE ‘Hepatitis B vaccination in adults and children: temporary recommendations from 21 August 2017’ (Gateway reference 2017256), which outlines recommendations on the prioritisation of vaccine for specific high risk groups in order to preserve adult and paediatric monovalent hepatitis B vaccine stock (available at https://www.gov.uk/government/publications/hepatitis-b-vaccine-recommendations-during-supply-constraints).

MSD has already made investments and taken steps to increase manufacturing capacity to meet growing demand, but it takes time for this new capacity to take full effect. MSD in the UK is working with the Department of Health and Public Health England to manage the supply vaccine of HBVAXPRO™ 10mcg. Therefore, we have introduced restrictions on the supply of HBVAXPRO™ 10mcg to ensure customers can vaccinate the highest risk priority groups, in line with the PHE recommendations. These customers will be able to access the vaccine via AAH, MSD’s nominated wholesaler. These restrictions will be reviewed on a regular basis. Supplies of HBVAXPRO™ 10mcg are expected to be restricted until further notice.

* Priority group 4 (with the exception of travel) including patients with chronic liver disease and household or sexual contacts of chronic hepatitis B cases, and other healthcare and frontline workers.